Faricimab for Treatment-Resistant Diabetic Macular Edema
Ryan B Rush,1– 3 Sloan W Rush1,2 1Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Southwest Retina Specialists, Amarillo, TX, USACorrespondence: Ryan B Rush, Southwest Retina Specialists, 7411 Wallace Blvd, Amarillo, TX...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-08-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/faricimab-for-treatment-resistant-diabetic-macular-edema-peer-reviewed-fulltext-article-OPTH |
| _version_ | 1798038751735185408 |
|---|---|
| author | Rush RB Rush SW |
| author_facet | Rush RB Rush SW |
| author_sort | Rush RB |
| collection | DOAJ |
| description | Ryan B Rush,1– 3 Sloan W Rush1,2 1Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Southwest Retina Specialists, Amarillo, TX, USACorrespondence: Ryan B Rush, Southwest Retina Specialists, 7411 Wallace Blvd, Amarillo, TX, 79106, USA, Tel +1 806 351-1870, Email ryan.rush.md@gmail.comPurpose: To assess the short-term outcomes in treatment-resistant diabetic macular edema (DME) patients changed from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF).Methods: A retrospective review was undertaken on DME subjects receiving IVA therapy at a single private practice. Patients were separated into study and control cohorts. Both study and control patients had received more than or equal to six IVA injections during the preceding 12 months, more than or equal to four IVA injections during the preceding 6 months, had a central macular thickness (CMT) on optical coherence tomography (OCT) of ≥ 300 μm, and had retinal fluid on OCT before cohort assignment. Study patients were switched to IVF and underwent three injections within 4 months, whereas control patients stayed on IVA during the same period and received three injections within 4 months.Results: There were 51 patients analyzed. There were 37.5% (9/24) in the study group and 3.7% (1/27) in the control group who achieved a CMT of less than 300 μm without retinal fluid on OCT at the end of the 4-month study (p=0.001). There were 41.7% (10/24) in the study group and 11.1% (3/27) in the control group who had gained two or more lines of visual acuity at the end of the 4-month study (p=0.01).Conclusion: For a significant minority, IVF can improve the short-term visual and anatomic outcomes in treatment-resistant DME patients formerly managed with IVA. Longer follow-up is needed to determine if such improvements can be preserved.Keywords: faricimab, treatment-resistant, diabetic macular edema, recalcitrance |
| first_indexed | 2024-04-11T21:44:33Z |
| format | Article |
| id | doaj.art-06796107abda40b18df1f7edb13a3f19 |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-04-11T21:44:33Z |
| publishDate | 2022-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-06796107abda40b18df1f7edb13a3f192022-12-22T04:01:28ZengDove Medical PressClinical Ophthalmology1177-54832022-08-01Volume 162797280177638Faricimab for Treatment-Resistant Diabetic Macular EdemaRush RBRush SWRyan B Rush,1– 3 Sloan W Rush1,2 1Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Southwest Retina Specialists, Amarillo, TX, USACorrespondence: Ryan B Rush, Southwest Retina Specialists, 7411 Wallace Blvd, Amarillo, TX, 79106, USA, Tel +1 806 351-1870, Email ryan.rush.md@gmail.comPurpose: To assess the short-term outcomes in treatment-resistant diabetic macular edema (DME) patients changed from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF).Methods: A retrospective review was undertaken on DME subjects receiving IVA therapy at a single private practice. Patients were separated into study and control cohorts. Both study and control patients had received more than or equal to six IVA injections during the preceding 12 months, more than or equal to four IVA injections during the preceding 6 months, had a central macular thickness (CMT) on optical coherence tomography (OCT) of ≥ 300 μm, and had retinal fluid on OCT before cohort assignment. Study patients were switched to IVF and underwent three injections within 4 months, whereas control patients stayed on IVA during the same period and received three injections within 4 months.Results: There were 51 patients analyzed. There were 37.5% (9/24) in the study group and 3.7% (1/27) in the control group who achieved a CMT of less than 300 μm without retinal fluid on OCT at the end of the 4-month study (p=0.001). There were 41.7% (10/24) in the study group and 11.1% (3/27) in the control group who had gained two or more lines of visual acuity at the end of the 4-month study (p=0.01).Conclusion: For a significant minority, IVF can improve the short-term visual and anatomic outcomes in treatment-resistant DME patients formerly managed with IVA. Longer follow-up is needed to determine if such improvements can be preserved.Keywords: faricimab, treatment-resistant, diabetic macular edema, recalcitrancehttps://www.dovepress.com/faricimab-for-treatment-resistant-diabetic-macular-edema-peer-reviewed-fulltext-article-OPTHfaricimabtreatment-resistantdiabetic macular edemarecalcitrance |
| spellingShingle | Rush RB Rush SW Faricimab for Treatment-Resistant Diabetic Macular Edema Clinical Ophthalmology faricimab treatment-resistant diabetic macular edema recalcitrance |
| title | Faricimab for Treatment-Resistant Diabetic Macular Edema |
| title_full | Faricimab for Treatment-Resistant Diabetic Macular Edema |
| title_fullStr | Faricimab for Treatment-Resistant Diabetic Macular Edema |
| title_full_unstemmed | Faricimab for Treatment-Resistant Diabetic Macular Edema |
| title_short | Faricimab for Treatment-Resistant Diabetic Macular Edema |
| title_sort | faricimab for treatment resistant diabetic macular edema |
| topic | faricimab treatment-resistant diabetic macular edema recalcitrance |
| url | https://www.dovepress.com/faricimab-for-treatment-resistant-diabetic-macular-edema-peer-reviewed-fulltext-article-OPTH |
| work_keys_str_mv | AT rushrb faricimabfortreatmentresistantdiabeticmacularedema AT rushsw faricimabfortreatmentresistantdiabeticmacularedema |